George Church: Combination Gene Therapy
Church-associated programs use AAV delivery of longevity-associated genes (FGF21, αKlotho, soluble TGF-β receptor 2) to treat multiple age-related diseases, with combination gene therapy proposed as a route to improved health span and longevity; Rejuvenate Bio, launched from Harvard's Wyss Institute, is linked to this work.
George Church holds a 0.99-confidence link to Gene Therapy in the Eternal Search graph. Church-associated programs use genome reading, writing, and editing platforms alongside adeno-associated virus (AAV) delivery of longevity-associated genes: FGF21, αKlotho, and soluble TGF-β receptor 2. The goal is treating multiple age-related diseases, with combination gene therapy proposed as a route to improved health span and longevity.
Rejuvenate Bio, launched from the Wyss Institute at Harvard, is linked to Church's gene therapy work. Publications connected to the Gene Therapy term in the graph include Rejuvenate Bio's own materials, a paper on the splicing variant of Klotho, and the publication "Noah Davidsohn - BioFuture."
Church's other neighboring terms in the graph: Epigenetic Rejuvenation, FOXO Signaling, TGF-beta Signaling, Apoptosis, Cell Therapy.
This edge resolves to a precise, publicly documented therapeutic payload (three named genes, AAV delivery, combination strategy) rather than a generic association, making it the clearest concrete illustration of what Church-associated gene therapy programs actually propose. The Rejuvenate Bio anchor and the cluster of neighboring terms (FOXO, TGF-beta, Epigenetic Rejuvenation) give the post a natural development arc from specific payload to broader research logic.